ALPHA TAU REPORTS COMPLETE LOCAL DISEASE CONTROL AND POSITIVE SAFETY PROFILE IN ALPHA DART® PANCREATIC CANCER TRIALS SHOWCASED AT DDW 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DRTS?
Source: moomoo
Local Disease Control Rate: Alpha Tau has announced a 100% local disease control rate in its clinical trials for the Alpha DaRT® pancreatic cancer treatment.
Safety Profile: The trials also demonstrated a favorable safety profile for the treatment, indicating minimal adverse effects on patients.
Presentation at Conference: These findings were presented at the DdW 2026 conference, highlighting the significance of the results in the field of cancer treatment.
Implications for Future Research: The positive outcomes from the trials may pave the way for further research and development of Alpha DaRT® in treating other types of cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.540
Low
5.00
Averages
7.00
High
9.00
Current: 8.540
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha DaRT Achieves Milestone in Pancreatic Cancer Trials
- Local Disease Control Rate: Alpha DaRT achieved a 100% local disease control rate in 19 evaluable patients across two first-in-human trials, highlighting its potential in treating pancreatic cancer, particularly in patients with extremely limited chemotherapy options.
- Favorable Safety Profile: Among 26 subjects treated, only 8 device-associated adverse events were reported, representing a 27% incidence, with nearly all events resolving within two weeks, indicating encouraging safety in heavily pre-treated patients.
- Clinical Integration Design: The therapy is designed for seamless integration into standard GI endoscopy workflows through an endoscopic ultrasound-guided procedure, facilitating easier adoption by clinicians and improving treatment accessibility for patients.
- International Conference Presentation: The clinical results of Alpha DaRT were presented for the first time at the 2026 Digestive Disease Week (DDW) conference, marking a significant recognition in the international gastroenterology field and further enhancing its prospects in pancreatic cancer treatment.
See More
ALPHA TAU REPORTS COMPLETE LOCAL DISEASE CONTROL AND POSITIVE SAFETY PROFILE IN ALPHA DART® PANCREATIC CANCER TRIALS SHOWCASED AT DDW 2026
Local Disease Control Rate: Alpha Tau has announced a 100% local disease control rate in its clinical trials for the Alpha DaRT® pancreatic cancer treatment.
Safety Profile: The trials also demonstrated a favorable safety profile for the treatment, indicating minimal adverse effects on patients.
Presentation at Conference: These findings were presented at the DdW 2026 conference, highlighting the significance of the results in the field of cancer treatment.
Implications for Future Research: The positive outcomes from the trials may pave the way for further research and development of Alpha DaRT® in treating other types of cancer.
See More
Alpha Tau Medical Announces Key Research Accepted at ASCO Annual Meeting
- Research Recognition: Alpha Tau Medical's abstract on Alpha DaRT treatment for pancreatic cancer has been accepted at the 2026 ASCO Annual Meeting, marking a significant endorsement of its scientific value in oncology, with publication expected on May 21, 2026.
- Clinical Data Compilation: The abstract presents pooled safety and efficacy data from three prospective clinical studies involving 58 patients in Canada and Israel, demonstrating the potential of Alpha DaRT in treating locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), thus advancing research in this critical area.
- Multicenter Trial Progress: The ongoing multicenter IMPACT trial in the U.S. evaluates the combination of Alpha DaRT with chemotherapy, while the ACAPELLA trial in France has treated its first patient, reflecting the company's strategic commitment to expanding its global clinical pipeline.
- Collaborative Development: The success of this research is attributed to the close collaboration among gastroenterology, medical oncology, and radiation oncology teams, indicating that the endoscopic ultrasound-guided intratumoral approach has been effectively integrated into clinical workflows, promising significant treatment options for the global medical community.
See More
Alpha Tau Medical Advances Pancreatic Cancer Research with Trial Expansion
- Trial Expansion Approval: Alpha Tau's IMPACT study received FDA approval to enroll an additional 10 patients, bringing total enrollment to 40, aimed at evaluating the safety and efficacy of its Alpha DaRT therapy in combination with chemotherapy, thereby providing new hope for treating advanced pancreatic cancer.
- Positive Market Reaction: Following the announcement of the trial expansion, shares of Alpha Tau Medical (DRTS) rose nearly 4% in pre-market trading, indicating strong retail investor interest and reflecting market confidence in the company's cancer treatment prospects.
- First Treatment in Europe: Alpha Tau successfully treated its first patient in the ACAPELLA trial, marking the debut of its Alpha DaRT therapy in Europe, targeting inoperable locally advanced pancreatic cancer patients who have completed standard chemotherapy, thus addressing a significant treatment gap.
- Significant Medical Need: Over 40,000 Europeans are diagnosed with inoperable locally advanced pancreatic cancer annually, and existing treatment options are inadequate to meet patient needs; the ACAPELLA trial aims to fill this critical healthcare gap and improve patient survival chances.
See More
Launch of ACAPELLA Clinical Trial for LAPC
- First Patient Treatment: The successful treatment of the first patient in the ACAPELLA trial at CHU Grenoble Alpes marks the first use of Alpha DaRT for pancreatic cancer in Europe, potentially introducing new treatment options in this critical area.
- Patient Population Size: With approximately 140,000 Europeans diagnosed with pancreatic cancer annually, and 30% presenting with locally advanced inoperable disease, the ACAPELLA trial aims to provide a new treatment pathway for these patients, addressing a significant unmet need.
- Clinical Trial Design: The ACAPELLA trial plans to enroll up to 40 patients to evaluate the safety of Alpha DaRT in combination with capecitabine, with the primary endpoint being the incidence of device-related serious adverse events, which holds substantial clinical significance.
- Global Strategic Expansion: This trial is a key component of Alpha Tau's clinical expansion strategy in Europe, alongside the ongoing IMPACT trial in the U.S., demonstrating the company's commitment to innovation in pancreatic cancer treatment.
See More
Alpha Tau Expands Pancreatic Cancer Clinical Trial
- Trial Size Expansion: The FDA's approval of Alpha Tau's IDE supplement increases the total patient count for the pancreatic cancer trial from 30 to 40, indicating the company's proactive approach in developing new therapies to meet high patient needs.
- New Treatment Exploration: The trial will evaluate the safety and efficacy of combining Alpha DaRT with standard chemotherapy agents gemcitabine/nab-paclitaxel in newly diagnosed patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma, potentially offering new treatment options for patients.
- Patient Recruitment Plan: Recruitment for the 40 patients is now expected to conclude in Q3 2026, despite earlier plans for Q2 completion, reflecting the company's adaptability in clinical research amid dependencies on clinical site approvals.
- Clear Clinical Objectives: The primary goals of the IMPACT study include assessing the feasibility of Alpha DaRT source implantation and monitoring for serious adverse events related to the device, further advancing Alpha Tau's strategic development in cancer treatment.
See More
Alpha DaRT Achieves Milestone in Pancreatic Cancer Trials
- Local Disease Control Rate: Alpha DaRT achieved a 100% local disease control rate in 19 evaluable patients across two first-in-human trials, highlighting its potential in treating pancreatic cancer, particularly in patients with extremely limited chemotherapy options.
- Favorable Safety Profile: Among 26 subjects treated, only 8 device-associated adverse events were reported, representing a 27% incidence, with nearly all events resolving within two weeks, indicating encouraging safety in heavily pre-treated patients.
- Clinical Integration Design: The therapy is designed for seamless integration into standard GI endoscopy workflows through an endoscopic ultrasound-guided procedure, facilitating easier adoption by clinicians and improving treatment accessibility for patients.
- International Conference Presentation: The clinical results of Alpha DaRT were presented for the first time at the 2026 Digestive Disease Week (DDW) conference, marking a significant recognition in the international gastroenterology field and further enhancing its prospects in pancreatic cancer treatment.
See More
ALPHA TAU REPORTS COMPLETE LOCAL DISEASE CONTROL AND POSITIVE SAFETY PROFILE IN ALPHA DART® PANCREATIC CANCER TRIALS SHOWCASED AT DDW 2026
Local Disease Control Rate: Alpha Tau has announced a 100% local disease control rate in its clinical trials for the Alpha DaRT® pancreatic cancer treatment.
Safety Profile: The trials also demonstrated a favorable safety profile for the treatment, indicating minimal adverse effects on patients.
Presentation at Conference: These findings were presented at the DdW 2026 conference, highlighting the significance of the results in the field of cancer treatment.
Implications for Future Research: The positive outcomes from the trials may pave the way for further research and development of Alpha DaRT® in treating other types of cancer.
See More
Alpha Tau Medical Announces Key Research Accepted at ASCO Annual Meeting
- Research Recognition: Alpha Tau Medical's abstract on Alpha DaRT treatment for pancreatic cancer has been accepted at the 2026 ASCO Annual Meeting, marking a significant endorsement of its scientific value in oncology, with publication expected on May 21, 2026.
- Clinical Data Compilation: The abstract presents pooled safety and efficacy data from three prospective clinical studies involving 58 patients in Canada and Israel, demonstrating the potential of Alpha DaRT in treating locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), thus advancing research in this critical area.
- Multicenter Trial Progress: The ongoing multicenter IMPACT trial in the U.S. evaluates the combination of Alpha DaRT with chemotherapy, while the ACAPELLA trial in France has treated its first patient, reflecting the company's strategic commitment to expanding its global clinical pipeline.
- Collaborative Development: The success of this research is attributed to the close collaboration among gastroenterology, medical oncology, and radiation oncology teams, indicating that the endoscopic ultrasound-guided intratumoral approach has been effectively integrated into clinical workflows, promising significant treatment options for the global medical community.
See More
Alpha Tau Medical Advances Pancreatic Cancer Research with Trial Expansion
- Trial Expansion Approval: Alpha Tau's IMPACT study received FDA approval to enroll an additional 10 patients, bringing total enrollment to 40, aimed at evaluating the safety and efficacy of its Alpha DaRT therapy in combination with chemotherapy, thereby providing new hope for treating advanced pancreatic cancer.
- Positive Market Reaction: Following the announcement of the trial expansion, shares of Alpha Tau Medical (DRTS) rose nearly 4% in pre-market trading, indicating strong retail investor interest and reflecting market confidence in the company's cancer treatment prospects.
- First Treatment in Europe: Alpha Tau successfully treated its first patient in the ACAPELLA trial, marking the debut of its Alpha DaRT therapy in Europe, targeting inoperable locally advanced pancreatic cancer patients who have completed standard chemotherapy, thus addressing a significant treatment gap.
- Significant Medical Need: Over 40,000 Europeans are diagnosed with inoperable locally advanced pancreatic cancer annually, and existing treatment options are inadequate to meet patient needs; the ACAPELLA trial aims to fill this critical healthcare gap and improve patient survival chances.
See More
Launch of ACAPELLA Clinical Trial for LAPC
- First Patient Treatment: The successful treatment of the first patient in the ACAPELLA trial at CHU Grenoble Alpes marks the first use of Alpha DaRT for pancreatic cancer in Europe, potentially introducing new treatment options in this critical area.
- Patient Population Size: With approximately 140,000 Europeans diagnosed with pancreatic cancer annually, and 30% presenting with locally advanced inoperable disease, the ACAPELLA trial aims to provide a new treatment pathway for these patients, addressing a significant unmet need.
- Clinical Trial Design: The ACAPELLA trial plans to enroll up to 40 patients to evaluate the safety of Alpha DaRT in combination with capecitabine, with the primary endpoint being the incidence of device-related serious adverse events, which holds substantial clinical significance.
- Global Strategic Expansion: This trial is a key component of Alpha Tau's clinical expansion strategy in Europe, alongside the ongoing IMPACT trial in the U.S., demonstrating the company's commitment to innovation in pancreatic cancer treatment.
See More
Alpha Tau Expands Pancreatic Cancer Clinical Trial
- Trial Size Expansion: The FDA's approval of Alpha Tau's IDE supplement increases the total patient count for the pancreatic cancer trial from 30 to 40, indicating the company's proactive approach in developing new therapies to meet high patient needs.
- New Treatment Exploration: The trial will evaluate the safety and efficacy of combining Alpha DaRT with standard chemotherapy agents gemcitabine/nab-paclitaxel in newly diagnosed patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma, potentially offering new treatment options for patients.
- Patient Recruitment Plan: Recruitment for the 40 patients is now expected to conclude in Q3 2026, despite earlier plans for Q2 completion, reflecting the company's adaptability in clinical research amid dependencies on clinical site approvals.
- Clear Clinical Objectives: The primary goals of the IMPACT study include assessing the feasibility of Alpha DaRT source implantation and monitoring for serious adverse events related to the device, further advancing Alpha Tau's strategic development in cancer treatment.
See More
